Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile NTRK1 - KHDRBS1
Therapy Crizotinib
Indication/Tumor Type sarcoma
Response Type predicted - sensitive


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 - KHDRBS1 sarcoma predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a patient with unclassified mesenchymal sarcoma harboring NTRK1-KHDRBS1 achieved a complete response after 3 months of Xalkori (crizotinib) treatment and remained on therapy and progression free at 45 months (PMID: 33941195). 33941195
PubMed Id Reference Title Details
(33941195) Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. Full reference...